Back to search

Peptide record

TPDB32803

Neuromedin N Anti-inflammatory Blood-Brain Barrier Neuropeptide Toxicity standard

6 amino acids

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB32803

Peptide_Name

Neuromedin N

Activity

Anti-inflammatory Blood-Brain Barrier Neuropeptide Toxicity

Activity_category_statistics

Immunity and inflammation peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides Neuroactive peptides

Database_Source

Peptipedia B3Pred BBPpredict ToxinPred 3.0

Sequence_Type

standard

Has_Modification No

Description A 6-aa standard natural multi-activity (Anti-inflammatory, Blood-Brain Barrier, Neuropeptide, and other sources) peptide sequence curated from Peptipedia, B3Pred, BBPpredict, and other sources, with an available 3D structural model.

Sequence

KIPYIL

FASTA

>TPDB32803|Anti-inflammatory;Blood-Brain Barrier;Neuropeptide;Toxicity|length=6
KIPYIL

Formula C38H63N7O8

Absent Amino Acids ARNDCEQGHMFSTWV

Common Amino Acids I

Mass 745.96

PI 9.74

Basic Residues 1

Acidic Residues 0

Hydrophobic Residues 4

Net Charge +1

Boman Index -0.68

Hydrophobicity 1.000

Aliphatic Index 195.00

Half Life

Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min

Extinction Coefficient Cystines 1490

Absorbance 280nm 199.74

Polar Residues 1

number

Amino Acid Distribution

A: 0 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 2 L: 1 K: 1 M: 0 F: 0 P: 1 S: 0 T: 0 W: 0 Y: 1 V: 0

Length

Formula

C38H63N7O8

Mass

745.96

9.74

Net Charge

Boman Index

-0.68

Hydrophobicity

1.000

Chemical_Mass

745.9464

Conformation

Linear

Monoisotopic_Mass

745.4723

Peptide_Length

Similarity

Peptide_Sequence_3Letter

Lys-Ile-Pro-Tyr-Ile-Leu

Evidence 1 Activity

Activity

Activity Endpoint EC50

Detail Source Activity Anti-inflammatory

Activity Measurement 0.00 µM

Detail Activity anti inflammatory

Activity Code ai

Source & Reference

Database Source NA

Authors Wei E. T., Thomas H. A.

Title Anti-inflammatory peptide agonists. Annu. Rev. Pharmacol. Toxicol., 33, 91-108

Year 1993

Literature Source Journal

Other

Number of Residues 6

Additional Info

BIOPEP-UWM database of bioactive peptides SMILES: [H][C@](N)(CCCCN)C(=O)N[C@@]([H])([C@@H](C)CC)C(=O)N1CCC[C@@]1([H])C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])([C@@H](C)CC)C(=O)N[C@@]([H])(CC(C)C)C(O)=O InChI=1S/C38H63N7O8/c1-7-23(5)31(36(50)42-29(38(52)53)20-22(3)4)43-34(48)28(21-25-14-16-26(46)17-15-25)41-35(49)30-13-11-19-45(30)37(51)32(24(6)8-2)44-33(47)27(40)12-9-10-18-39/h14-17,22-24,27-32,46H,7-13,18-21,39-40H2,1-6H3,(H,41,49)(H,42,50)(H,43,48)(H,44,47)(H,52,53)/t23-,24-,27-,28-,29-,30-,31-,32-/m0/s1 InChIKey=RZMLVIHXZGQADB-YLUGYNJDSA-N

Evidence 2 Activity

Activity

Detail Source Activity Blood-Brain Barrier

Activity Result 0.042 min-1

Assay & Model

In Vitro Method Efflux study ICU

Animal Model Origin/Source

Response Brain elemination rate constant

Source & Reference

Database Source NA

Source B3Pdb

Other

Source Origin human

Transport Type Permeability

Label Direct iodination

Evidence 3 Activity

Activity

Detail Source Activity Blood-Brain Barrier

Activity Result 88.87%

Assay & Model

In Vitro Method Capillary depletion

Animal Model Origin/Source

Response % parenchyma

Source & Reference

Database Source NA

Source B3Pdb

Other

Source Origin human

Label Direct iodination

Evidence 4 Activity

Activity

Detail Source Activity Blood-Brain Barrier

Activity Result 11.22%

Assay & Model

In Vitro Method Capillary depletion

Animal Model Origin/Source

Response % capillary

Source & Reference

Database Source NA

Source B3Pdb

Other

Source Origin human

Label Direct iodination

Evidence 5 Activity

Activity

Detail Source Activity Blood-Brain Barrier

Activity Result 0.02299 ml/(g x min)

Assay & Model

Animal Model Origin/Source

Response Unidirectional influx rate constant,initial

Source & Reference

Database Source NA

Source B3Pdb

Other

Source NeuroPepV2

Other

Organism Source Rattus norvegicus

Family Neurotensin

Family

Neurotensin

In_Vivo_Mode_of_Delivery

Intravenous

Number_of_Residues